These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17316284)

  • 1. The CARI guidelines. Calcineurin inhibitors in renal transplantation: adverse effects.
    Jose M;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S66-74. PubMed ID: 17316284
    [No Abstract]   [Full Text] [Related]  

  • 2. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
    Coates PT;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
    [No Abstract]   [Full Text] [Related]  

  • 3. The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors.
    Grimer M;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S98-S105. PubMed ID: 17316288
    [No Abstract]   [Full Text] [Related]  

  • 4. The CARI guidelines. Choice of calcineurin inhibitors in adult renal transplantation: effects on transplant outcomes.
    Pilmore H;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S88-97. PubMed ID: 17316287
    [No Abstract]   [Full Text] [Related]  

  • 5. The CARI guidelines. Calcineurin inhibitors in paediatric renal transplantation.
    McTaggart S;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S106-10. PubMed ID: 17316270
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcineurin inhibitor toxicity in renal allografts: morphologic clues from protocol biopsies.
    Sharma A; Jain S; Gupta R; Guleria S; Agarwal S; Dinda A
    Indian J Pathol Microbiol; 2010; 53(4):651-7. PubMed ID: 21045386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side effects of immunosuppression--what patients really think.
    Newstead CG
    Nephron Clin Pract; 2004; 97(2):c31-2. PubMed ID: 15218326
    [No Abstract]   [Full Text] [Related]  

  • 8. The CARI guidelines. Calcineurin inhibitors in renal transplantation: therapeutic drug monitoring.
    Trevillian P;
    Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S57-65. PubMed ID: 17316283
    [No Abstract]   [Full Text] [Related]  

  • 9. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
    Bai JP; Lesko LJ; Burckart GJ
    Pharmacotherapy; 2010 Feb; 30(2):195-209. PubMed ID: 20099993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L
    G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive strategies in renal transplantation at the beginning of the third millennium.
    Abramowicz D; Wissing KM; Broeders N
    Adv Nephrol Necker Hosp; 2000; 30():9-28. PubMed ID: 11068631
    [No Abstract]   [Full Text] [Related]  

  • 14. Sirolimus conversion for renal preservation in liver transplantation: not so fast.
    Jensen GS; Wiseman A; Trotter JF
    Liver Transpl; 2008 May; 14(5):601-3. PubMed ID: 18433068
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.
    Ferrari U; Empl M; Kim KS; Sostak P; Förderreuther S; Straube A
    Headache; 2005 Mar; 45(3):211-4. PubMed ID: 15836594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity.
    Klein IH; Abrahams AC; van Ede T; Oey PL; Ligtenberg G; Blankestijn PJ
    J Hypertens; 2010 Sep; 28(9):1928-34. PubMed ID: 20577127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Calcineurin inhibitor nephrotoxicity in renal allografts].
    Takeda A; Morozumi K
    Nihon Jinzo Gakkai Shi; 2011; 53(4):610-4. PubMed ID: 21688481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.